- Home
- SAGE vs PGEN Comparison
SAGE vs PGEN Comparison
Compare SAGE & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- PGEN
- Stock Information
- Founded
- SAGE 2010
- PGEN 1998
- Country
- SAGE United States
- PGEN United States
- Employees
- SAGE N/A
- PGEN N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- PGEN Health Care
- Exchange
- SAGE Nasdaq
- PGEN Nasdaq
- Market Cap
- SAGE 415.0M
- PGEN 344.0M
- IPO Year
- SAGE 2014
- PGEN N/A
- Fundamental
- Price
- SAGE $7.79
- PGEN $1.50
- Analyst Decision
- SAGE Hold
- PGEN Strong Buy
- Analyst Count
- SAGE 19
- PGEN 4
- Target Price
- SAGE $9.88
- PGEN $7.33
- AVG Volume (30 Days)
- SAGE 1.2M
- PGEN 1.4M
- Earning Date
- SAGE 04-29-2025
- PGEN 05-13-2025
- Dividend Yield
- SAGE N/A
- PGEN N/A
- EPS Growth
- SAGE N/A
- PGEN N/A
- EPS
- SAGE N/A
- PGEN N/A
- Revenue
- SAGE $41,243,000.00
- PGEN $3,925,000.00
- Revenue This Year
- SAGE $100.64
- PGEN $189.12
- Revenue Next Year
- SAGE $70.19
- PGEN $1,093.07
- P/E Ratio
- SAGE N/A
- PGEN N/A
- Revenue Growth
- SAGE N/A
- PGEN N/A
- 52 Week Low
- SAGE $4.62
- PGEN $0.65
- 52 Week High
- SAGE $14.97
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- SAGE 56.30
- PGEN 49.93
- Support Level
- SAGE $7.56
- PGEN $1.33
- Resistance Level
- SAGE $7.89
- PGEN $1.65
- Average True Range (ATR)
- SAGE 0.36
- PGEN 0.14
- MACD
- SAGE 0.06
- PGEN 0.03
- Stochastic Oscillator
- SAGE 88.03
- PGEN 72.22
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.